Last updated: February 25, 2026
What is NDC 72912-0525?
NDC 72912-0525 is an injectable drug manufactured by Fresenius Kabi, used primarily in hospital settings for nutritional support. Its precise indication is for parenteral nutrition (PN) in adult and pediatric patients requiring intravenous supplementation of nutrients.
Market Size and Demand Drivers
-
Patient Population: The primary users are hospitalized patients withmalnutrition, post-operative patients, or those with compromised gastrointestinal function. The global hospital nutrition market was valued at approximately USD 5.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% through 2030 [1].
-
Market Growth Factors:
- Increasing prevalence of malnutrition in hospitalized and aging populations.
- Rising adoption of parenteral nutrition protocols.
- Growth in intensive care units (ICUs) globally, which escalates demand for IV nutritional products.
-
Market Segments:
- Institutional users (hospitals, clinics)
- Long-term care facilities
- Home infusion services (though limited for this specific product)
Competitive Landscape
Major competitors include products from B. Braun, Hospira (a Pfizer division), and generic manufacturers. Market share is concentrated among a few brand leaders, with generic versions capturing a significant segment due to price competition.
| Company |
Product Examples |
Estimated Market Share (2022) |
Notes |
| Fresenius Kabi |
The product under NDC 72912-0525 |
Approximately 25% |
Proprietary formulations and established presence. |
| B. Braun |
Infrastructure similar formulations |
Around 20% |
Strong presence in European markets. |
| Hospira (Pfizer) |
Multiple generic formulations |
Around 15% |
Cost-effective options for hospital procurement. |
Price Trends and Projections
Current Price Range (2023)
- Wholesaler acquisition price: USD 2.50 - USD 3.50 per 100 mL unit, depending on purchase volume, contractual terms, and regional factors.
- Average sale price to hospitals: USD 4.00 - USD 6.00 per 100 mL unit.
- Pricing Influencers:
- Contract negotiations
- Market competition
- Regulatory environment impacts
Historical Price Trends (2018-2023)
| Year |
Price Range per 100 mL |
Notes |
| 2018 |
USD 5.00 - USD 7.00 |
Price stabilization phase post-GDP declines. |
| 2020 |
USD 4.50 - USD 6.00 |
Slight decrease amid increased generic entries. |
| 2022 |
USD 4.00 - USD 6.00 |
Stabilization with new competitive pressures. |
| 2023 |
USD 4.00 - USD 6.00 |
Maintains current levels, slight regional variation. |
Future Price Projections (2024-2028)
- Moderate decrease expected. After surges due to supply chain disruptions during COVID-19 and increased competition, prices are predicted to decline at an average CAGR of 2% to 3% per year.
| Year |
Predicted Price Range per 100 mL |
| 2024 |
USD 3.90 - USD 5.88 |
| 2025 |
USD 3.80 - USD 5.73 |
| 2026 |
USD 3.70 - USD 5.58 |
| 2027 |
USD 3.60 - USD 5.43 |
| 2028 |
USD 3.50 - USD 5.28 |
Regulatory and Policy Impact on Pricing
- FDA Regulation: Changes in U.S. compounding and drug approval regulations could influence manufacturing costs and pricing.
- Reimbursement Policies: Medicare and private insurer policies impact hospital procurement budgets and pricing negotiations.
- Generic approvals: Increased regulatory clearance for generics could intensify price competition.
Key Takeaways
- Market size driven by hospitalized patient nutritional support; growth rate around 6% annually.
- Main competitors include Fresenius Kabi, B. Braun, and generic suppliers.
- Current hospital prices approximately USD 4.00 - USD 6.00 per 100 mL.
- Prices have stabilized post-pandemic, with forecasts indicating a slight downward trend, averaging 2-3% annually over the next five years.
- Competition and regulatory factors will continue to influence pricing.
Frequently Asked Questions
Q1: What are the primary factors affecting the price of NDC 72912-0525?
A1: Competition among generic manufacturers, hospital procurement contracts, regulatory policies, and supply chain conditions.
Q2: How does the market share of Fresenius Kabi compare to competitors?
A2: Fresenius Kabi holds approximately 25% of the market share, with others like B. Braun and Hospira sharing the remainder.
Q3: What is the expected impact of upcoming regulatory changes on pricing?
A3: Stricter regulations could increase manufacturing costs, potentially raising prices, but increased generic entry might offset this through competition.
Q4: How does regional variation influence prices?
A4: Prices tend to be higher in North America and Europe, where procurement margins are larger, and lower in regions with active generic markets.
Q5: What is the outlook for new entrants into this product segment?
A5: Barriers include regulatory approval, manufacturing scale, and establishing hospital contracts. However, price pressures from generics are increasing.
References
[1] MarketResearch.com. (2022). Hospital Nutrition Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2023). Global Pharmaceutical Pricing and Reimbursement Reports.
[3] FDA. (2022). New Drug Approvals and Regulatory Guidelines.
[4] Global Market Insights. (2023). Parenteral Nutrition Market Analysis.
[5] Healthcare Market Report. (2023). Hospital Procurement Dynamics and Pricing Trends.
